Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. (Q45895252)

From Wikidata

Jump to navigation Jump to search

scientific article published on 2 December 2013

Language	Label	Description	Also known as
English	Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial.	scientific article published on 2 December 2013

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295850%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295850%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Helicobacter pylori

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Ivan Fan Ngai Hung

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295850%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295850%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Wai Keung Leung

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295850%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Kevin S H Liu

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295850%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Teresa Tong

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295850%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Axel S J Hsu

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295850%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Frank Y F Lam

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295850%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

David Y K But

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295850%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

S Y Wong

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295850%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

language of work or name

0 references

publication date

2 December 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295850%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295850%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

63

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295850%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295850%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1410-1415

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295850%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Helicobacter pylori treatment in the era of increasing antibiotic resistance

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Review article: the treatment of refractory Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Treatment of Helicobacter pylori infection 2012.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

The antimicrobial susceptibility of Helicobacter pylori in Hong Kong (1997-2001).

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Should quinolones come first in Helicobacter pylori therapy?

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

A rapid, low-dose, 13C-urea tablet for the detection of Helicobacter pylori infection before and after treatment

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-306120

21 January 2018

Identifiers

10.1136/GUTJNL-2013-306120

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295850%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24295850%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45895252&oldid=1401833245"